Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01396577 · ClinicalTrials.gov registry record · Phase 1
Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT01396577 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 54 participants.
The verdict
NCT01396577, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to determine that three 2-mg tablets of perampanel are bioequivalent to one 6-mg tablet of perampanel.
Interventions
- DRUG perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01396577
The ClinicalTrials.gov registry entry for NCT01396577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which perampanel is the first listed.
NCT01396577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01396577 about?
NCT01396577 is a clinical study titled "Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects". The purpose of this study is to determine that three 2-mg tablets of perampanel are bioequivalent to one 6-mg tablet of perampanel.
What is the current status of trial NCT01396577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2010-12. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01396577?
The interventions under investigation include: perampanel (DRUG).
Who is sponsoring clinical trial NCT01396577?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.